Position in MRNA
as of Mar 31, 2026
· filed May 14, 2026
Position Value
$0
+$0 QoQ
Shares Held
0
Ownership
0.000%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Mar 2021
8 quarters on record
Derivatives in MRNA
reported options exposure · as of Mar 31, 2026CallValue
$40,640,000
CallShares
800,000
PutValue
$0
PutShares
0
Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.
Position in Biotechnology
Healthcare · as of Mar 31, 2026Affinity Asset Advisors, LLC holds $1,518,254,571 across 81 Biotechnology names.
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | APGE |
Apogee Therapeutics, Inc.
|
1,284,926 | $108,152,221 | |
| 2 | XENE |
Xenon Pharmaceuticals Inc.
|
1,675,000 | $97,401,250 | |
| 3 | ERAS |
Erasca, Inc.
|
5,350,000 | $86,563,000 | |
| 4 | INSM |
INSMED Inc
|
480,000 | $78,489,600 | |
| 5 | ROIV |
Roivant Sciences Ltd.
|
2,800,000 | $77,560,000 | |
| 6 | SYRE |
Spyre Therapeutics, Inc.
|
1,279,134 | $64,519,518 | |
| 7 | CNTA |
Centessa Pharmaceuticals plc
|
1,400,000 | $55,608,000 | |
| 8 | PRAX |
Praxis Precision Medicines, Inc.
|
170,000 | $54,772,300 |
All Filings in MRNA
Export CSV
8 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $40,640,000 | 800,000 | Call | Sole | 2026-05-14 | |
| 2024-03-31 | $42,624,000 | 400,000 | Put | Sole | 2024-05-14 | |
| 2023-03-31 | $5,375,300 | 35,000 | Call | Sole | 2023-05-15 | |
| 2022-12-31 | $5,388,600 | 30,000 | Put | Sole | 2023-02-13 | |
| 2022-06-30 | $2,142,750 | 15,000 | Call | Sole | 2022-08-12 | |
| 2021-12-31 | $7,619,400 | 30,000 | Put | Sole | 2022-02-11 | |
| 2021-06-30 | $2,937,250 | 12,500 | Call | Sole | 2021-08-13 | |
| 2021-03-31 | $654,750 | 5,000 | Call | Sole | 2021-05-14 | |
| No filing history on record for this holder in this stock. | ||||||